Since the functional defects in TP53 and RB1, through mutations such as TP53 R175H (a dominant-negative mutation) and RB1 gene loss, are recognized as critical licensing factors for the lineage transition to NECs from other cancer types [11, 39], we incorporated these genetic alterations into our models. This evidence concerns the gene RB1 and cancer.